Genpharm and the Saudi Society for Dermatology forge a Strategic partnership to enhance dermatological care in Saudi Arabia
- The partnership aims to advance patient care and dermatological standards in the Kingdom.
- The partnership will focus on increasing awareness of dermatological diseases through ongoing medical education.
- A signing ceremony was held and attended by over 150 healthcare professionals and esteemed guests.
- The event marked the launch of Adtralza®, a new treatment for atopic dermatitis, into the Saudi market.
Riyadh, Saudi Arabia: November 26, 2024: Genpharm, a GCC-based pharmaceutical company and leader in market access across the Middle East, North Africa and Turkey, and the Saudi Society for Dermatology and Dermatological Surgery (SSDDS), have announced a strategic partnership aimed at advancing dermatological healthcare in Saudi Arabia.
The partnership will benefit both patients and healthcare providers alike. It will focus on implementing Continuing Medical Education (CME) activities for healthcare professionals, improving patient care, and introducing innovative treatments.
A signing ceremony was held at the Narcissus The Royal Hotel in Riyadh, and was attended by over 150 healthcare professionals, including prominent international and local key opinion leaders in dermatology. The presence of Denmark’s Ambassador to Saudi Arabia, Her Excellency Liselotte Plesner, highlighted the significance of this collaboration.
Karim Smaira, CEO & Co-founder of Genpharm, emphasized the significance of the partnership, stating, “Our partnership with SSDDS marks a significant step towards enhancing dermatological care in Saudi Arabia. We are committed to improving patient outcomes and supporting healthcare professionals with the latest advancements in treatment. Our continuous educational efforts will ensure that healthcare providers are well-equipped to offer optimized treatment to their patients.”
The event also marked Genpharm’s launch of Adtralza®, an innovative treatment for moderate to severe atopic dermatitis developed by LEO Pharma, into the Saudi market. The introduction of Adtralza® marks an innovation in atopic dermatitis therapy in Saudi Arabia, potentially improving the quality of life for those suffering from the condition.
Dr. Ruaa Al Harithy, Vice President of SSDDS, highlighted the organization’s dedication to advancing dermatology, saying, “The Saudi Society of Dermatology and Dermatologic Surgery (SSDDS), a leading organization dedicated to the advancement of dermatology in the Kingdom of Saudi Arabia, is proud to highlight its ongoing commitment to the medical field and its growing partnerships with key industry players. Through education, research, and clinical excellence, the SSDDS has been at the forefront of advancing dermatological practices in the region and improving patient outcomes.
As the premier professional body for dermatologists in Saudi Arabia, the SSDDS provides a platform for the dissemination of scientific knowledge and fosters collaboration among healthcare professionals, researchers, and industry leaders. The Society supports continuous medical education, organizes conferences, and provides specialized training, ensuring that members stay at the cutting edge of dermatology practices and innovations in dermatologic surgery.
The SSDDS also plays an integral role in promoting public awareness about skin health, advocating for early recognition of skin diseases, and ensuring that the public has access to the most advanced, evidence-based dermatological treatments available.
In its continuous effort to enhance the quality of dermatological care, the Saudi Society of Dermatology and Dermatologic Surgery is pleased to announce an important partnership with Genpharm, a leader in the pharmaceutical industry. This collaboration underscores the SSDDS’s commitment to fostering relationships with trusted industry partners who share a common goal of improving healthcare outcomes.
Genpharm, with its extensive portfolio of dermatology-focused products and expertise in cutting-edge pharmaceutical developments, aligns with the SSDDS’s mission to provide the highest quality dermatological care. Together, they aim to push the boundaries of skin health, offering innovative treatments, advancing research, and delivering enhanced patient care across Saudi Arabia.”
Dr. Abdullah Al Aqeel, President of SSDDS, expressed enthusiasm about the collaboration, noting, “We are excited about the opportunities that this partnership with Genpharm will bring. This collaboration strengthens our shared commitment to advancing skin health through innovation, education, and research.
The partnership will involve both entities working closely on various initiatives, including clinical trials, the development of new treatment modalities, and the organization of educational events for healthcare professionals. Furthermore, through this collaboration, the SSDDS aims to ensure that Saudi patients have access to the latest dermatological advancements and benefit from the highest standards of care.
As the Saudi Society of Dermatology and Dermatologic Surgery continues to grow and evolve, it remains dedicated to its mission of promoting excellence in dermatological care and advancing the practice of dermatology in the Kingdom. The SSDDS looks forward to the positive impact of its partnership with Genpharm.”
Dr. Issam R. Hamadah, Consultant Dermatologist at King Faisal Specialist Hospital & Research Centre, remarked, “I am pleased that pharmaceutical companies are pursuing therapeutic solutions for common dermatologic diseases, which have high impact on those afflicted, their families, and society in general. Having new medications like Adtralza will be quite beneficial to all.”
Combined with the introduction of Adtralza® in the Kingdom, the partnership highlights Genpharm and SSDDS’ dedication to improving patient care and healthcare outcomes through innovative treatments and continuous medical education.
Ends
About Genpharm
Genpharm provides fast-track market access to rare disease and specialty pharmaceutical companies looking to expand into the Middle East and North Africa (MENA region) and Turkey. It is the regional leader in rare diseases and the first regional company to introduce gene therapy expertise into the region. Incorporated since 2012, a financially sound and privately owned company, Genpharm is based in the Dubai Science Park (DSP), UAE. It also has an office in Boston, USA, in the heart of the biotech hub and in The Republic of Ireland. Operating through evidence-based medicine and with the highest ethical standards, Genpharm provides its partners with fast and sustainable market access solutions across the region.
Genpharm employs highly qualified and experienced MSLs and KAMs. It offers regulatory, medical, PV and logistical support. Armed with knowledge of the local business culture and the vast network of trusted partners, Genpharm’s expertise allows it to create market opportunities for innovative healthcare products and services. Current partners include, Argenx, Amicus, Apellis, Orchard Therapeutics, LEO, Sarepta, PTC, Ultragenyx, Rhythm, Pharming, Quoin and others.
For more info on the Middle East Pharmaceutical market and Genpharm business model and services, visit genpharmservices.com
About Saudi Society for Dermatology and Dermatological Surgery (SSDDS)
The Saudi Society for Dermatology and Surgery was established in the year 1409 AH, corresponding to 1989 AD. Since its establishment, the Society has taken upon itself the responsibility of achieving the scientific and social goals for which it was established, including, for example, contributing to the movement of scientific progress in the field of skin diseases, and carrying out the necessary studies and research to prevent some diseases. Skin diseases and developing treatments for incurable diseases, especially those endemic in the Kingdom. It holds scientific meetings and specialized seminars and conducting training courses in advanced centers in the field of developments in the specialty of dermatology, highlighting the specialty of skin diseases and surgery, and carrying out the necessary studies to raise the level of performance in the specialty, as well as providing advice regarding the specialty of skin diseases and surgery to governmental and private institutions. And also for individuals.
Headquarters of the Saudi Society of Dermatology and Surgery
Saudi Society of Dermatology and Surgery
Diplomatic Quarter – P.O. Box 94648 – Riyadh 11614
Association phone: 011/488 3553
Association fax: 1410 482/011
The Society’s website is www.ssdds.org
The association’s email address is [email protected]
The current headquarters of the Saudi Society of Dermatology and Surgery
Imam Saud Road – Al-Nimr Al-Nakhil Building
